"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 18 | 18 |
| 2004 | 0 | 57 | 57 |
| 2005 | 0 | 62 | 62 |
| 2006 | 1 | 57 | 58 |
| 2007 | 0 | 70 | 70 |
| 2008 | 1 | 79 | 80 |
| 2009 | 2 | 105 | 107 |
| 2010 | 0 | 88 | 88 |
| 2011 | 1 | 113 | 114 |
| 2012 | 2 | 90 | 92 |
| 2013 | 2 | 114 | 116 |
| 2014 | 0 | 130 | 130 |
| 2015 | 0 | 136 | 136 |
| 2016 | 0 | 153 | 153 |
| 2017 | 0 | 116 | 116 |
| 2018 | 0 | 141 | 141 |
| 2019 | 1 | 134 | 135 |
| 2020 | 0 | 119 | 119 |
| 2021 | 0 | 116 | 116 |
| 2022 | 0 | 40 | 40 |
| 2023 | 0 | 54 | 54 |
| 2024 | 0 | 98 | 98 |
| 2025 | 0 | 122 | 122 |
| 2026 | 0 | 64 | 64 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis Through Symbiotic Adhesion and Reverse Migration. Cancer Res. 2026 Aug 14; 86(16):4007-4027.
-
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models. Blood. 2026 Aug 06; 148(6):751-766.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. Mol Cancer Ther. 2026 Aug 04; 25(8):1342-1356.
-
SYNCRIP drives ferroptosis resistance and metabolic activation via SIRT1 and HK2 in glioblastoma. Int J Biol Sci. 2026; 22(12):6670-6688.
-
Glioblastoma stem cell growth requires DOT1L-MED23 control of enhancer accessibility. Cell Rep. 2026 Jul 28; 45(7):117647.
-
Nuclear-specific reductive carboxylation of alpha-ketoglutarate fuels histone acetylation to induce chromatin accessibility and gene activation. Nat Commun. 2026 Jul 01; 17(1).
-
KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/?-catenin signaling pathway. Clin Exp Med. 2026 Jun 28; 26(1).
-
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma. Nat Commun. 2026 Jun 26; 17(1).
-
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma. Oncoimmunology. 2026 Dec 31; 15(1):2688603.